Literature DB >> 27979826

miR-200b inhibits TNF-α-induced IL-8 secretion and tight junction disruption of intestinal epithelial cells in vitro.

Yujie Shen1, Min Zhou1, Junkai Yan2, Zizhen Gong2, Yongtao Xiao2, Cong Zhang1, Peng Du3, Yingwei Chen4,2.   

Abstract

Inflammatory bowel diseases (IBDs) are chronic, inflammatory disorders of the gastrointestinal tract with unclear etiologies. Intestinal epithelial cells (IECs), containing crypt and villus enterocytes, occupy a critical position in the pathogenesis of IBDs and are a major producer of immunoregulatory cytokines and a key component of the intact epithelial barrier. Previously, we have reported that miR-200b is involved in the progression of IBDs and might maintain the integrity of the intestinal epithelial barrier via reducing the loss of enterocytes. In this study, we further investigated the impact of miR-200b on intestinal epithelial inflammation and tight junctions in two distinct differentiated states of Caco-2 cells after TNF-α treatment. We demonstrated that TNF-α-enhanced IL-8 expression was decreased by microRNA (miR)-200b in undifferentiated IECs. Simultaneously, miR-200b could alleviate TNF-α-induced tight junction (TJ) disruption in well-differentiated IECs by reducing the reduction in the transepithelial electrical resistance (TEER), inhibiting the increase in paracellular permeability, and preventing the morphological redistribution of the TJ proteins claudin 1 and ZO-1. The expression levels of the JNK/c-Jun/AP-1 and myosin light chain kinase (MLCK)/phosphorylated myosin light chain (p-MLC) pathways were attenuated in undifferentiated and differentiated enterocytes, respectively. Furthermore, a dual-luciferase reporter gene detection system provided direct evidence that c-Jun and MLCK were the specific targets of miR-200b. Collectively, our results highlighted that miR-200b played a positive role in IECs via suppressing intestinal epithelial IL-8 secretion and attenuating TJ damage in vitro, which suggested that miR-200b might be a promising strategy for IBD therapy. NEW & NOTEWORTHY: This was the first time that the inhibitory role of miR-200b on intestinal epithelial inflammation and paracellular permeability has been reported. Moreover, we further divided the intestinal epithelial cells (IECs) into two differentiated conditions and investigated the distinct impacts of miR-200b. Finally, we put forward and proved that myosin light chain kinase (MLCK) was a novel target of miR-200b.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  IL-8; TNF-α; intestinal epithelial cell; miR-200b; tight junction

Mesh:

Substances:

Year:  2016        PMID: 27979826     DOI: 10.1152/ajpgi.00316.2016

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  20 in total

1.  MiR-200b in heme oxygenase-1-modified bone marrow mesenchymal stem cell-derived exosomes alleviates inflammatory injury of intestinal epithelial cells by targeting high mobility group box 3.

Authors:  Dong Sun; Huan Cao; Liu Yang; Ling Lin; Bin Hou; Weiping Zheng; Zhongyang Shen; Hongli Song
Journal:  Cell Death Dis       Date:  2020-06-25       Impact factor: 8.469

Review 2.  Role of zonula occludens in gastrointestinal and liver cancers.

Authors:  Amit Kumar Ram; Balasubramaniyan Vairappan
Journal:  World J Clin Cases       Date:  2022-04-26       Impact factor: 1.534

3.  Perspective: Milk microRNAs as Important Players in Infant Physiology and Development.

Authors:  Christine Leroux; Mathilde Lea Chervet; J Bruce German
Journal:  Adv Nutr       Date:  2021-10-01       Impact factor: 8.701

4.  Protective effect of Bombyx mori gloverin on intestinal epithelial cells exposure to enterotoxigenic E. coli.

Authors:  Qian Lin; Qingqing Fu; Guoqi Su; Daiwen Chen; Bing Yu; Yuheng Luo; Ping Zheng; Xiangbing Mao; Zhiqing Huang; Jie Yu; Junqiu Luo; Hui Yan; Jun He
Journal:  Braz J Microbiol       Date:  2021-06-21       Impact factor: 2.214

Review 5.  From inflammatory bowel disease to colorectal cancer: what's the role of miRNAs?

Authors:  Mostafa Vaghari-Tabari; Niloufar Targhazeh; Soheila Moein; Durdi Qujeq; Forough Alemi; Maryam Majidina; Simin Younesi; Zatollah Asemi; Bahman Yousefi
Journal:  Cancer Cell Int       Date:  2022-04-11       Impact factor: 5.722

6.  The Protective Influence of Chondroitin Sulfate, a Component of Human Milk, on Intestinal Bacterial Invasion and Translocation.

Authors:  Kathryn Y Burge; Lindsey Hannah; Jeffrey V Eckert; Aarthi Gunasekaran; Hala Chaaban
Journal:  J Hum Lact       Date:  2019-05-03       Impact factor: 2.219

Review 7.  Roles of microRNAs in inflammatory bowel disease.

Authors:  HyunTaek Jung; Jae Seok Kim; Keum Hwa Lee; Kalthoum Tizaoui; Salvatore Terrazzino; Sarah Cargnin; Lee Smith; Ai Koyanagi; Louis Jacob; Han Li; Sung Hwi Hong; Dong Keon Yon; Seung Won Lee; Min Seo Kim; Paul Wasuwanich; Wikrom Karnsakul; Jae Il Shin; Andreas Kronbichler
Journal:  Int J Biol Sci       Date:  2021-05-17       Impact factor: 6.580

8.  Multi-endpoint analysis of human 3D airway epithelium following repeated exposure to whole electronic vapor product aerosol or cigarette smoke.

Authors:  Lukasz Czekala; Roman Wieczorek; Liam Simms; Fan Yu; Jessica Budde; Edgar Trelles Sticken; Kathryn Rudd; Thomas Verron; Oleg Brinster; Matthew Stevenson; Tanvir Walele
Journal:  Curr Res Toxicol       Date:  2021-02-20

9.  High glucose levels increase influenza-associated damage to the pulmonary epithelial-endothelial barrier.

Authors:  Katina D Hulme; Limin Yan; Rebecca J Marshall; Conor J Bloxham; Kyle R Upton; Sumaira Z Hasnain; Helle Bielefeldt-Ohmann; Zhixuan Loh; Katharina Ronacher; Keng Yih Chew; Linda A Gallo; Kirsty R Short
Journal:  Elife       Date:  2020-07-22       Impact factor: 8.140

10.  Regulation of Colonic Mucosal MicroRNA Expression via Multiple Targets in Visceral Hypersensitivity Rats by Tongxieyaofang.

Authors:  Guanqun Chao; Yingying Wang; Fangxu Ye; Shuo Zhang
Journal:  Yonsei Med J       Date:  2018-10       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.